Market Overview

Infinity Reports Encouraging Phase 1 IPI-145 Data at ASH

Infinity
Pharmaceuticals (NASDAQ: INFI) today announced updated data
from a Phase 1 study of IPI-145, its oral inhibitor of
phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with
chronic lymphocytic leukemia (CLL), a potentially fatal hematologic
malignancy (blood cancer). Data from the study showed that IPI-145 was
highly active in patients with relapsed/refractory CLL, with a nodal
response rate of 89 percent and an overall response rate of 48 percent
as defined by the International Workshop on Chronic Lymphocytic Leukemia
(IWCLL) criteria1, including one complete response and 12
partial responses, among patients receiving IPI-145 at doses ≤ 25 mg
twice daily (BID). Onset of activity was rapid, with the majority of
responses occurring in less than two

See full press release

Posted-In: News Guidance Contracts Management Global

 

Most Popular

Related Articles (INFI)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters